Data443 Announces General Availability of Vaikora, an AI Runtime Enforcement Platform for Agentic AI

Data443 Risk Mitigation, Inc. (ATDS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Data443 Announces General Availability of Vaikora, an AI Runtime Enforcement Platform for Agentic AI Inline allow, block and constrain controls for AI actions, data flows and agent-to-agent communication — with an audit record for every enforced decision RESEARCH TRI

Original reporting
Published Oct 14, 2026, 12:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ATDS
Neutral
medium confidence
Mentioned
$ATDS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ATDSNeutralLow
01

Why it matters

The product launch is the first public disclosure, offering a new revenue stream but facing execution risk and limited liquidity.

02

Market read

A micro‑cap OTC filing announcing a new AI control platform; likely low immediate market impact.

03

What to watch

Potential strategic partnerships with cloud providers could accelerate adoption beyond current expectations.

Relevance 4/10Novelty 4/10Timing: today

Background

Data443 Risk Mitigation, a data security software firm, serves over 10,000 customers and has acquired several assets. The Vaikora platform aims to enforce AI actions at runtime.

Company-level read

Ticker impact

$ATDSNeutralMedium confidence
Context

Data443 Risk Mitigation announced the general availability of its AI runtime enforcement platform Vaikora.

Expected impact

likely modest pressure as investors assess market demand and execution risk

Evidence & confidence

The announcement is the first disclosure of the product, but the company is a penny‑stock with limited cash and uncertain adoption.

Market effects

introduces a niche AI governance solution; limited immediate impact on broader AI or security sectors

primarily U.S. OTC market; no broader regional effect

minimal, as the company is small and product adoption is unproven

Counterpoint

The platform could capture a growing compliance niche, driving upside if major cloud partners adopt it.

Key entities

  • Data443 Risk Mitigation, Inc.

    Provider of data security and AI runtime enforcement solutions.

  • Jason Remillard

    CEO and founder of Data443, quoted on the product launch.

Related articles

$MTVAHighAI 8/10

MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial ​ Adding to Previously Reported 68.1% Liver Fat Reduction and Strengthening Its Liver Profile for MetALD ​ Additional Phase 1 Part 3B Da

$QCOMMed

Qualcomm CEO: Elon Musk is serious about SpaceX's cellular network ambitions

Qualcomm (QCOM) CEO Cristiano Amon stated that SpaceX (SPCX) is serious about entering the cellular business with its Starlink project. Qualcomm signed a multiyear deal with SpaceX to supply equipment for Starlink's planned 5G network, set to deploy in 2027. SpaceX is reportedly in talks with tower owners Crown Castle (CCI) and American Tower (AMT) for leasing space on 80,000 cell sites. Analysts view these moves as significant commitments by SpaceX to build a nationwide terrestrial network.

$MTVAHighAI 8/10

MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial

MetaVia Inc. (MTVA) reported additional positive data from its Phase 1 Part 3B clinical trial of DA-1726, showing a 1.47 mg/dL placebo-adjusted reduction in uric acid (p<0.001) after 16 weeks. The trial also demonstrated a 68.1% reduction in liver fat, 13.5% weight loss, and improvements in HbA1c. MetaVia plans to begin a Phase 2 study in MetALD and ALD in the second half of 2027.